Maravai Lifesciences Holdings, Inc.

As of September 11, 2025, Maravai Lifesciences Holdings, Inc. is in a mildly bearish trend, with daily moving averages indicating bearishness, while its year-to-date return is -47.16%, significantly underperforming the S&P 500's 12.22%.

As of February 22, 2024, Maravai Lifesciences Holdings, Inc. is considered risky and overvalued with poor financial metrics and a year-to-date stock performance of -47.16%, significantly underperforming compared to the S&P 500's 12.22% return.

As of February 22, 2024, Maravai Lifesciences Holdings, Inc. is considered overvalued and risky due to negative financial metrics, including a Price to Book Value of 2.02, an EV to Sales ratio of 2.56, and poor performance indicators like a -27.14% ROCE and -34.98% ROE, alongside a year-to-date stock return of -61.28% compared to the S&P 500's 2.44%.

As of June 20, 2025, Maravai Lifesciences Holdings, Inc. is in a bearish trend with moderate strength, indicated by daily moving averages and Bollinger Bands, despite some mixed signals from MACD and KST.

Maravai Lifesciences Holdings, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $47 million and a net loss of $53 million as of March 2025. The company has a market cap of $532.24 million and no dividend yield.

As of Jun 18, Maravai Lifesciences Holdings, Inc. has a market capitalization of 532.24 million, with net sales of 241.86 million and a net profit of -289.79 million over the latest four quarters. The company's shareholder's funds are 325.29 million, and total assets amount to 1,008.24 million.